Qing (Joanna) Zhou FDA

Dr. Qing Zhou is a review chief in the Office of Biotechnology Products (OBP) at FDA’s Center for Drug Evaluation and Research (CDER). Dr. Zhou joined the FDA in 2010 as an Interagency Oncology Taskforce (IOTF) fellow. She became a product quality reviewer in the Division of Monoclonal Antibody (DMA), OBP/CDER/FDA, in 2012 and was selected to serve as a team leader in 2015. Dr. Zhou has extensive research experience in the areas of tumor and transplantation immunology and immunotherapy. Currently, she supervises a group of primary reviewers and team leaders to perform the review of regulatory submissions at the FDA for a wide range of novel and biosimilar biotechnology products.